MedTrace Logo

Influence of Fampridine on Working Memory in Healthy Subjects

NCT04516603 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-05

No results posted yet for this study

Summary

Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants.

The hypotheses is that fampridine improves working memory performance.

Conditions

  • Working Memory

Interventions

DRUG

Fampridine SR

Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).

DRUG

Placebo

no active component

Sponsors & Collaborators

  • Clinical Trial Unit, University Hospital Basel, Switzerland

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Prof. Dominique de Quervain, MD

    lead OTHER

Principal Investigators

  • Dominique de Quervain, Prof · University of Basel, Transfaculty Research Platform

  • Andreas Papassotiropoulos, Prof · University of Basel, Transfacutly Research Platform

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2040-01-01
Primary Completion
2041-12-31
Completion
2041-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516603 on ClinicalTrials.gov